PharmaShots Weekly Snapshots (May 29 - June 02, 2023)
Date: June 02, 2023 | Tags: Impact Therapeutics, Eikon Therapeutics, IMP1734, Pharma, China, Hong Kong, Macau, Taiwan
Date: June 02, 2023 | Tags: BMS, Camzyos, Mavacamten, Obstructive Hypertrophic Cardiomyopathy, Regulatory, NICE
Date: June 02, 2023 | Tags: Pfizer, Aztreonam-Avibactam, Bacterial Infections, Clinical Trial, P-III, REVISIT, ASSEMBLE Study
Date: June 02, 2023 | Tags: Innovent, Merck KGaA, IBI351, Erbitux, cetuximab, NSCLC, Regulatory, KRASG12C, China
Date: June 02, 2023 | Tags: TG Therapeutics, Briumvi, ublituximab-xiiy, Multiple Sclerosis, Regulatory, EC, Approval
Date: June 02, 2023 | Tags: Bayer, Cedilla Therapeutics, CyclinE1/CDK2, Complex Inhibitors, Biotech
Date: June 01, 2023 | Tags: Ionis, Donidalorsen, Hereditary Angioedema, Clinical Trial, P-II, OLE Study, OASIS-HAE Study
Date: June 01, 2023 | Tags Nykode Therapeutics, Roche, VB10.16, atezolizumab, Advanced Cervical Cancer, Pharma
Date: June 01, 2023 | Tags: Precigen, PRGN-2009, Pembrolizumab, Cervical Cancer, Regulatory, US, FDA, IND
Date: June 01, 2023 | Tags: C4 Therapeutics, Betta, CFT8919, Non-Small Cell Lung Cancer, Pharma
Pfizer’s Vydura (rimegepant) Receives the NICE Recommendation for the Prevention of Migraine Attacks
Date: June 01, 2023 | Tags: Pfizer, Vydura, Rimegepant, erenumab, fremanezumab, galcanezumab, Migraine, Regulatory, NICE
Date: June 01, 2023 | Tags: InDex Pharmaceuticals, Viatris, Ulcerative Colitis, Cobitolimod, Pharma, Japan, CONCLUDE program
Date: May 31, 2023 | Tags: Janssen, Macitentan, Tadalafil, Pulmonary Arterial Hypertension, Regulatory, US, FDA, NDA
XtalPi Collaborated with Eli Lilly on AI Drug Discovery for ~$250M
Date: May 31, 2023 | Tags: XtalPi, Eli Lilly, AI Drug Discover, ~$250M, ID4Inno small-molecule drug discovery platform, Biotech
Date: May 31, 2023 | Tags: Abbvie, Rinvoq, upadacitinib, Systemic Lupus Erythematosus, Clinical Trial, P-II, SLEek Study
Sanofi Reports P-II Study Results of Frexalimab for the Treatment of Relapsing Multiple Sclerosis
Date: May 31, 2023 | Tags: Sanofi, Frexalimab, Relapsing Multiple Sclerosis, Clinical Trial, P-II Study
Date: May 31, 2023 | Tags: BMS, Repotrectinib, Non-Small Cell Lung Cancer, Regulatory, Priority Review, US, FDA, NDA
Date: May 31, 2023 | Tags: Stealth BioTherapeutics, Pharmanovia, Elamipretide, Pharma, Barth Syndrome, EU, MENA
Pfizer Reports P-III Trial (BASIS) Results of Marstacimab for the Treatment of Hemophilia A and B
Date: May 30, 2023 | Tags: Pfizer, Marstacimab, Hemophilia A, Hemophilia B, Clinical Trial, P-III, BASIS Trial
Date: May 30, 2023 | Tags: Samsung Bioepis, Epysqli, biosimilar, eculizumab, Paroxysmal Nocturnal Hemoglobinuria, Regulatory, Biosimilar, EC, Marketing Authorization
Sun Pharma Entered into a License Agreement with Philogen to Commercialize Nidlegy for Skin Cancers
Date: May 30, 2023 | Tags: Sun Pharma, Philogen, Nidlegy, Daromun, skin cancers, Pharma
Date: May 30, 2023 | Tags: Marinus, Ztalmy, ganaxolone, Seizures, CDKL5 Deficiency Disorder, Regulatory, EMA, CHMP
Date: May 30, 2023 | Tags: Novo Nordisk, Sogroya, Norditropin, somapacitan, Growth Hormone Deficiency, Regulatory, EMA, CHMP
Date: May 30, 2023 | Tags: AstraZeneca, Ultomiris, ravulizumab, neuromyelitis optica spectrum disorder, Regulatory, MHLW, Approval
Date: May 29, 2023 | Tags: Harbour BioMed, Porustobart, HBM4003, Toripalimab, Hepatocellular Carcinoma, Clinical Trial, ASCO 2023
Date: May 29, 2023 | Tags: HanAll Biopharma, Daewoong, NurrOn, HL161, HL036, Pharma, Parkinson's Disease
Date: May 29, 2023 | Tags: BMS, Opdivo, nivolumab, Resectable Non-Small Cell Lung Cancer, Regulatory, EMA, CHMP
Date: May 29, 2023 | Tags: Iovance Biotherapeutics, Lifileucel, Advanced Melanoma, Regulatory, Priority Review. US, FDA, BLA
AstraZeneca Reports P-III Trial (DUO-E) Results of Imfinzi (durvalumab) + Lynparza (olaparib) for Advanced Endometrial Cancer
Date: May 29, 2023 | Tags: AstraZeneca, Imfinzi, durvalumab, Lynparza, Olaparib, Advanced Endometrial Cancer, Clinical Trial, P-III, DUO-E Trial
Date: May 29, 2023 | Tags: BMS, Reblozyl, luspatercept-aamt, Anemia, MDS, ASCO, EHA, 2023, Clinical Trial, P-III, COMMANDS Study
Related Post: PharmaShots Weekly Snapshots (May 22 - 26, 2023)
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.